Results 61 to 70 of about 21,874 (160)

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, Volume 20, Issue 7, Page 1667-1693, July 2026.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BMC Cancer, 2018
Background Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug.
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O’Leary, Frankie A Holmes, Virginia Espina, Lance A Liotta, Joyce O’Shaughnessy, Clair Gallagher, Lorraine O’Driscoll, Sweta Rani, Stephen F Madden, Neil A O’Brien, Charles Ginther, Dennis Slamon, Naomi Walsh, William M Gallagher, Radoslaw Zagozdzon, William R Watson, Norma O’Donovan, John Crown   +21 more
doaj   +1 more source

Lapatinib-induced enhancement of mitochondrial respiration in HER2-positive SK-BR-3 cells: mechanism revealed by analysis of proteomic but not transcriptomic data

Frontiers in Molecular Biosciences
Dual inhibitors of HER2 and EGFR, such as lapatinib, have shown significant efficacy for the therapy of HER2-positive breast cancer. Previous experiments showed that in cell cultures, the efficacy of lapatinib was significantly reduced by exposure to ...
Dmitry Kamashev, Dmitry Kamashev, Dmitry Kamashev, Nina Shaban, Nina Shaban, Galina Zakharova, Alexander Modestov, Alexander Modestov, Мargarita Kamynina, Sergey Baranov, Sergey Baranov, Anton Buzdin, Anton Buzdin, Anton Buzdin, Anton Buzdin, Anton Buzdin   +15 more
doaj   +1 more source

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

BMC Cancer, 2010
Background There is strong evidence demonstrating that activation of epidermal growth factor receptors (EGFRs) leads to tumor growth, progression, invasion and metastasis.
Collantes Maria, Peñuelas Ivan, Catena Raul, Redrado Miriam, Manrique Irene, Perez-Stable Carlos, Parrondo Ricardo, Nguewa Paul A, Diaz Roque, Díaz-González Juan, Calvo Alfonso   +10 more
doaj   +1 more source

Lapatinib in breast cancer

Annals of Oncology, 2007
Aberrant activation of some members of human epidermal growth factor receptor (HER) family plays a key role in breast carcinogenesis. Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2.
Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., Manzione, L.   +5 more
openaire   +3 more sources

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

PLoS ONE, 2017
BackgroundOverexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23% of breast cancers and these cancers are classified as HER2-positive breast cancer. Trastuzumab is the first-line targeted therapeutic drug for
Tatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, Ken Suzawa, Takahiro Yoshioka, Shuta Tomida, Xiaojiang Cui, Ramachandran Murali, Kei Namba, Hiroki Sato, Hidejiro Torigoe, Mototsugu Watanabe, Kazuhiko Shien, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Yoshihisa Kitamura, Shinichiro Miyoshi, Toshiaki Sendo, Shinichi Toyooka   +19 more
doaj   +1 more source

Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines

Open Veterinary Journal
Background: Canine prostatic carcinoma (cPC) is a urogenital tumor with poor prognosis, for which no effective treatment has been established. Recently, it has been shown that human epidermal growth factor receptor type 2 (HER2) is overexpressed in cPC ...
Kenjiro Kaji, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +4 more
doaj   +1 more source

Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.

PLoS ONE
The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and progression in several tumor types, including prostate cancer (PC). Trastuzumab and other anti-HER2 therapies, such as lapatinib, have been used in human breast cancer
Carlos Eduardo Fonseca-Alves, Antonio Fernando Leis-Filho, Zara Alves Lacerda, Patricia de Faria Lainetti, Renee Laufer Amorim, Silvia Regina Rogatto   +5 more
doaj   +1 more source

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

PLoS ONE, 2010
The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance. Cellular adaptations that allow breast cancer cell to survive prolonged HER2 inhibition include de-repression of the transcription ...
Alessio Nencioni, Michele Cea, Anna Garuti, Mario Passalacqua, Lizzia Raffaghello, Debora Soncini, Eva Moran, Gabriele Zoppoli, Vito Pistoia, Franco Patrone, Alberto Ballestrero   +10 more
doaj   +1 more source

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

Cancer Management and Research, 2010
Catherine Oakman, Marta Pestrin, Elena Zafarana, Egidia Cantisani, Angelo Di Leo“Sandro Pitigliani” Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, ItalyAbstract: Lapatinib is a dual
Catherine Oakman, Marta Pestrin, Elena Zafarana, et al   +3 more
doaj